OSU 6162

Drug Profile

OSU 6162

Alternative Names: Movement disorder therapeutics - Pfizer; PNU-9639; PNU-96391; PNU-96391A

Latest Information Update: 22 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Carlsson Research AB
  • Developer Carlsson Research AB; NeuroSearch; Pfizer
  • Class Antipsychotics; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor modulators; Dopamine D2 receptor partial agonists; Serotonin 2 receptor modulators; Serotonin 2A receptor partial agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic fatigue syndrome; Stroke
  • Discontinued Parkinson's disease

Most Recent Events

  • 11 Jul 2017 Oslo University Hospital plans a phase II trial for Fatigue (secondary to aneurysmal subarachnoid haemorrhage) in Norway (NCT03209830)
  • 20 Mar 2017 Phase-II clinical trials in Stroke in Sweden (PO) (EudraCT2016-003888-19)
  • 04 Feb 2016 OSU 6162 is still in phase II trials for Chronic fatigue syndrome in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top